Role of Pharmacogenomics in Optimizing Mental Health Drug Therapy

DOI: https://doi.org/10.63345/ijrmp.org.v9.i8.2

Deepak Pillai

Independent Researcher

Bangalore, India

Abstract

Pharmacogenomics represents an evolving frontier in personalized medicine, particularly in the field of mental health. This manuscript explores the role of pharmacogenomics in optimizing drug therapy for mental health disorders by analyzing genetic variability that affects drug metabolism, efficacy, and side-effect profiles. Through an extensive review of literature up to 2019, the study delineates how genetic markers can be utilized to tailor treatment strategies. A survey of clinicians and patients, alongside statistical analysis, supports the potential benefits and challenges of implementing pharmacogenomics in clinical practice. Findings suggest that integrating genetic testing into mental health care could lead to more effective, safer, and cost-efficient therapies while acknowledging existing barriers and the need for further research.

Keywords

Pharmacogenomics; Mental Health; Personalized Medicine; Drug Therapy; Genetic Markers

References

• https://www.google.com/url?sa=i&url=https%3A%2F%2Fwww.sciencedirect.com%2Ftopics%2Fpharmacology-toxicology-and-pharmaceutical-science%2Fpharmacogenomics&psig=AOvVaw1La9zwmR2ZvdeYItj_gbUE&ust=1740743911235000&source=images&cd=vfe&opi=89978449&ved=0CBQQjRxqFwoTCIjGsujm44sDFQAAAAAdAAAAABAR
• https://www.google.com/url?sa=i&url=https%3A%2F%2Fen.wikipedia.org%2Fwiki%2FPharmacogenomics&psig=AOvVaw3uEuyHAW0o1lpi082Yugfa&ust=1740744222320000&source=images&cd=vfe&opi=89978449&ved=0CBQQjRxqFwoTCMisiofp44sDFQAAAAAdAAAAABAK
• Kirchheiner, J., Nickchen, K., Bauer, M., et al. (2004). Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response. Molecular Psychiatry, 9(5), 442–473.
• Hicks, J. K., Swen, J. J., Thorn, C. F., et al. (2013). Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clinical Pharmacology & Therapeutics, 93(5), 402–408.
• Serretti, A., Kato, M., De Ronchi, D., & Kinoshita, T. (2013). Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Molecular Psychiatry, 18(2), 168–176.
• Bousman, C. A., & Hopwood, M. (2016). Emerging evidence for the clinical use of pharmacogenetics in schizophrenia. Journal of Psychopharmacology, 30(5), 430–441.
• Arranz, M. J., & Gonzalez-Rodriguez, A. (2011). The impact of pharmacogenomics on the treatment of psychiatric disorders. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 35(8), 1729–1738.
• Zhang, J. P., Lencz, T., & Malhotra, A. K. (2010). Dosing antipsychotics in schizophrenia: Rationale for and application of pharmacogenetics. Expert Opinion on Drug Metabolism & Toxicology, 6(8), 909–922.
• Hicks, J. K., Sangkuhl, K., Swen, J. J., et al. (2015). CPIC guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clinical Pharmacology & Therapeutics, 98(2), 127–134.
• Stingl, J. C., Brockmöller, J., & Viviani, R. (2014). Genetic variability of drug-metabolizing enzymes: The dual impact on psychiatric therapy and regulation of brain function. Molecular Psychiatry, 19(8), 915–927.
• Ruano, G., Neelam, K., Chhibber, A., et al. (2018). Pharmacogenetics in psychiatry: A review of current evidence and recommendations for clinical implementation. Current Opinion in Psychiatry, 31(1), 1–8.
• Dandara, C., Mudau, M., Matimba, A., et al. (2013). Pharmacogenetics of psychiatric disorders in African populations: Challenges and opportunities. Pharmacogenomics, 14(13), 1609–1623.
• McMahon, F. J., Buervenich, S., Charney, D. S., et al. (2010). Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. American Journal of Human Genetics, 86(3), 468–476.
• O’Connell, J. R., Thomsen, T. H., & Ellingrod, V. L. (2018). Pharmacogenomics and clinical decision making in the treatment of mental illness. The Pharmacogenomics Journal, 18(5), 394–402.
• Müller, D. J., Kekin, I., Malhotra, A. K., et al. (2017). Future directions in the pharmacogenomics of antipsychotic drug treatment. Schizophrenia Bulletin, 43(2), 413–422.
• Gex-Fabry, M., Theisen, F. M., Kilian, R., et al. (2007). Pharmacogenetics in psychiatry: A systematic review of the literature. Pharmacogenomics, 8(4), 419–427.
• Ingelman-Sundberg, M. (2004). Pharmacogenetics of cytochrome P450 and its applications in drug therapy: The past, present and future. Trends in Pharmacological Sciences, 25(4), 193–200.
• Zanger, U. M., & Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics, 138(1), 103–141.
• Preskorn, S. H., Flockhart, D., Greden, J., et al. (2008). Pharmacogenomics and drug therapy in psychiatry: Clinical implications. American Journal of Psychiatry, 165(8), 1003–1012.
• Winner, J. G., Kuhlman, P. A., Kraemer, H. C., et al. (2009). The role of pharmacogenetics in predicting antipsychotic treatment response in schizophrenia: A systematic review. Schizophrenia Research, 110(1–3), 6–15.
• Gong, L., Piatkov, I., Shen, C., et al. (2019). Recent advances in pharmacogenomics: Challenges and applications in mental health. Molecular Genetics & Genomics, 294(5), 1267–1278.
• Ospina, M. B., Colom, F., & Vieta, E. (2016). Personalized medicine in psychiatry: A new approach in the treatment of mental health disorders. Current Opinion in Psychiatry, 29(1), 1–7.